Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List (NRDL) in 2017; the company’s USD 129 million investment in a new innovation center in Shanghai, the third strategic innovation hub in their global network; and the role that China can play within the Group’s global expansion and commitment to ‘delivering innovative medicines to more patients faster’.
One could say we were able to ride the wave of the recent healthcare reforms
